AR and prostate carcinoma: Of note, it was shown that the use of S1R antagonists prevented nuclear translocation of androgen receptor (AR), induced proteasomal degradation of AR and its splice variant, ARV7 (frequently detected in castrate-resistant prostate cancer), and consequently suppressed their transcriptional activity (Thomas et al., 2017).